

Hamzah Abu-Sbeih

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8893648/publications.pdf>

Version: 2024-02-01

78
papers

2,975
citations

516215

16
h-index

288905

40
g-index

81
all docs

81
docs citations

81
times ranked

2595
citing authors

#	ARTICLE	IF	CITATIONS
1	Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. <i>Nature Medicine</i> , 2018, 24, 1804-1808.	15.2	521
2	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. , 2021, 9, e002435.		298
3	Endoscopic and Histologic Features of Immune Checkpoint Inhibitor-Related Colitis. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 1695-1705.	0.9	177
4	Immune-checkpoint inhibitor-induced diarrhea and colitis in patients with advanced malignancies: retrospective review at MD Anderson. , 2018, 6, 37.		174
5	Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. , 2018, 6, 142.		146
6	Importance of endoscopic and histological evaluation in the management of immune checkpoint inhibitor-induced colitis. , 2018, 6, 95.		146
7	Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis. <i>Journal of Clinical Oncology</i> , 2019, 37, 2738-2745.	0.8	138
8	Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease. <i>Journal of Clinical Oncology</i> , 2020, 38, 576-583.	0.8	135
9	Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. , 2019, 7, 93.		131
10	Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. , 2018, 6, 103.		130
11	Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. <i>Cancer Cell</i> , 2022, 40, 509-523.e6.	7.7	115
12	Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. , 2019, 7, 31.		94
13	Characteristics, aetiologies and trends of hepatocellular carcinoma in patients without cirrhosis: a United States multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 809-821.	1.9	77
14	Can Immune Checkpoint Inhibitors Induce Microscopic Colitis or a Brand New Entity?. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 385-393.	0.9	63
15	Impact of antibiotic therapy on the development and response to treatment of immune checkpoint inhibitor-mediated diarrhea and colitis. , 2019, 7, 242.		60
16	Clinical Characteristics and Adverse Impact of Hepatotoxicity due to Immune Checkpoint Inhibitors. <i>American Journal of Gastroenterology</i> , 2020, 115, 251-261.	0.2	58
17	Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 553-561.	2.0	57
18	Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 538-545.	0.6	51

#	ARTICLE	IF	CITATIONS
19	The Impact of Immune Checkpoint Inhibitor-Related Adverse Events and Their Immunosuppressive Treatment on Patientsâ€™ Outcomes. <i>Journal of Immunotherapy and Precision Oncology</i> , 2018, 1, 7-18.	0.6	40
20	Systematic review with meta-analysis: effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced enterocolitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1432-1452.	1.9	28
21	Immune Checkpoint Inhibitors-Induced Hepatitis. <i>Advances in Experimental Medicine and Biology</i> , 2018, 995, 159-164.	0.8	26
22	Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment. , 2019, 7, 118.		26
23	Immune-checkpoint inhibitors induced diarrhea and colitis. <i>Current Opinion in Gastroenterology</i> , 2020, 36, 25-32.	1.0	21
24	Immune Checkpoint Inhibitors-Induced Colitis. <i>Advances in Experimental Medicine and Biology</i> , 2018, 995, 151-157.	0.8	19
25	Clinical Features of Rituximab-associated Gastrointestinal Toxicities. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 539-545.	0.6	19
26	Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 700-708.	2.3	19
27	Management Considerations for Immune Checkpoint Inhibitor-Induced Enterocolitis Based on Management of Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 662-668.	0.9	18
28	Clinical Review on the Utility of Fecal Microbiota Transplantation in Immunocompromised Patients. <i>Current Gastroenterology Reports</i> , 2019, 21, 8.	1.1	17
29	Safety of endoscopy in cancer patients with thrombocytopenia and neutropenia. <i>Gastrointestinal Endoscopy</i> , 2019, 89, 937-949.e2.	0.5	16
30	Recurrent <i>Clostridium difficile</i> infection is associated with treatment failure and prolonged illness in cancer patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 128-134.	0.8	13
31	Cap-fitted endoscopic mucosal resection of 20-mm colon flat lesions followed by argon plasma coagulation results in a low adenoma recurrence rate. <i>Endoscopy International Open</i> , 2020, 08, E115-E121.	0.9	13
32	Gut Microbiome and Immune Checkpoint Inhibitor-Induced Enterocolitis. <i>Digestive Diseases and Sciences</i> , 2020, 65, 797-799.	1.1	13
33	Gastrointestinal Adverse Events Observed After Chimeric Antigen Receptor T-Cell Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 789-796.	0.6	12
34	Clinical characteristics of colitis induced by taxane-based chemotherapy. <i>Annals of Gastroenterology</i> , 2019, 33, 59-67.	0.4	12
35	Gastrointestinal toxic effects in patients with cancer receiving platinum-based therapy. <i>Journal of Cancer</i> , 2020, 11, 3144-3150.	1.2	9
36	Neutropenic Enterocolitis: Clinical Features and Outcomes. <i>Diseases of the Colon and Rectum</i> , 2020, 63, 381-388.	0.7	8

#	ARTICLE	IF	CITATIONS
37	Outcomes of Immune Checkpoint Inhibitor-related Diarrhea or Colitis in Cancer Patients With Superimposed Gastrointestinal Infections. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 402-408.	0.6	7
38	Gastrointestinal Injury Related to Antiangiogenesis Cancer Therapy. <i>Clinical Colorectal Cancer</i> , 2020, 19, e117-e123.	1.0	6
39	Interleukin-6 is potential target to de-couple checkpoint inhibitor-induced colitis from antitumor immunity.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2616-2616.	0.8	6
40	Vedolizumab Achieved Clinical and Histologic Remission in a Patient with Lung Cancer Who Had a Steroid-Refractory Upper Gastrointestinal Injury Due to Nivolumab Treatment. <i>Journal of Immunotherapy and Precision Oncology</i> , 2019, 2, 40-45.	0.6	6
41	Gastrointestinal Tract Adverse Events. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 247-253.	0.8	5
42	Patients with breast cancer may be at higher risk of colorectal neoplasia. <i>Annals of Gastroenterology</i> , 2019, 32, 400-406.	0.4	5
43	Gastrointestinal, pancreatic, and hepatic toxicity profile of CTLA-4 immune checkpoint inhibitors alone and in combination with PD-1/PD-L1 inhibitors: A meta-analysis of clinical trials.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14117-e14117.	0.8	4
44	Outcomes after early initiation of nonsteroidal immunosuppressive therapy in patients with immune checkpoint inhibitor-induced colitis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2571-2571.	0.8	4
45	Hepatobiliary Adverse Events. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1244, 271-276.	0.8	3
46	P105 SHORT TERM ENDOSCOPIC FOLLOW UP ON IMMUNO-CHECKPOINT INHIBITOR INDUCED COLITIS POST TREATMENT. <i>Inflammatory Bowel Diseases</i> , 2018, 24, S37-S37.	0.9	2
47	Rate of colorectal neoplasia in patients with Hodgkin lymphoma. <i>Colorectal Disease</i> , 2020, 22, 154-160.	0.7	2
48	Immune-mediated colitis after resumption of immune checkpoint inhibitor therapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 2577-2577.	0.8	2
49	P053 IMMUNO-CHECKPOINT INHIBITORS INDUCED COLITIS TREATED WITH MESALAMINE. <i>Inflammatory Bowel Diseases</i> , 2018, 24, S19-S19.	0.9	1
50	Patients with Non-Hodgkin's Lymphoma Are at Risk of Adenomatous Colon Polyps. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2965-2971.	1.1	1
51	Reply to Y. Inagaki et al. <i>Journal of Clinical Oncology</i> , 2020, 38, 1749-1750.	0.8	1
52	Clinical Characteristics and Outcomes of Eosinophilic Colitis in Patients With Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2021, 44, 395-401.	0.6	1
53	Outcomes of immune-checkpoint inhibitor induced organ toxicities.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10063-10063.	0.8	1
54	Outcomes of Vedolizumab Treatment in Patients With Immune Checkpoint Inhibitor-Induced Diarrhea and Colitis: A Multi-Center Study. <i>American Journal of Gastroenterology</i> , 2018, 113, S58.	0.2	1

#	ARTICLE	IF	CITATIONS
55	The Importance of Endoscopic and Histological Evaluation in the Management of Immune Checkpoint Inhibitor-Induced Colitis. American Journal of Gastroenterology, 2018, 113, S112-S113.	0.2	1
56	Long-Term Outcome of Mucinous Pancreatic Cystic Lesions in Cancer Survivors or Patients With Extra-Pancreatic Malignancy. American Journal of Gastroenterology, 2018, 113, S52.	0.2	1
57	Tu1723 - Endoscopic and Histologic Characterization of Immunotherapy-Induced Colitis. Gastroenterology, 2018, 154, S-1000-S-1001.	0.6	0
58	P052 IMMUNO-CHECKPOINT INHIBITOR INDUCED COLITIS IN A PATIENT WITH LUNG CANCER AND COLON METASTASIS TREATED WITH MESALAMINE: A CASE STUDY. Inflammatory Bowel Diseases, 2018, 24, S19-S19.	0.9	0
59	Tu1199 COMPARISON OF THE SUCCESS OF ENDOSCOPIC TREATMENT IN EARLY ESOPHAGEAL SQUAMOUS CELL CANCER AND ESOPHAGEAL ADENOCARCINOMA. A NINE YEARS EXPERIENCE FROM A CANCER HOSPITAL. Gastrointestinal Endoscopy, 2018, 87, AB567-AB568.	0.5	0
60	Features of Microscopic Colitis in Cancer Patients Receiving Immune Checkpoint Inhibitors. American Journal of Gastroenterology, 2018, 113, S67.	0.2	0
61	P103 ROLE OF INFLIXIMAB IN THE MANAGEMENT OF IMMUNE-CHECKPOINT INHIBITORS-MEDIATED COLITIS (ICI-C). Inflammatory Bowel Diseases, 2018, 24, S36-S37.	0.9	0
62	534 SAFETY OF ENDOSCOPIC PROCEDURES IN CANCER PATIENTS WITH THROMBOCYTOPENIA: A TERTIARY CARE CANCER CENTER EXPERIENCE. Gastrointestinal Endoscopy, 2018, 87, AB92-AB93.	0.5	0
63	Mo1107 PREDICTORS OF OVERALL SURVIVAL IN CANCER PATIENTS WHO HAD ENDOSCOPIC EVALUATION IN THE SETTING OF NEUTROPENIA AND THROMBOCYTOPENIA. Gastrointestinal Endoscopy, 2018, 87, AB398-AB399.	0.5	0
64	Tu1148 ENDOSCOPIC MUCOSAL RESECTION AND RADIOFREQUENCY ABLATION ARE SAFE AND EFFECTIVE IN CURATIVE TREATMENT OF EARLY ESOPHAGEAL ADENOCARCINOMA. Gastrointestinal Endoscopy, 2018, 87, AB541-AB542.	0.5	0
65	Mo1932 - Multiple Recurrent Clostridium Difficile Infection is Associated with Treatment Failure and Prolonged Illness in Cancer Patients. Gastroenterology, 2018, 154, S-855-S-856.	0.6	0
66	P103 ROLE OF INFLIXIMAB IN THE MANAGEMENT OF IMMUNE-CHECKPOINT INHIBITORS-MEDIATED COLITIS (ICI-C). Gastroenterology, 2018, 154, S52-S53.	0.6	0
67	924 SAFETY OF ENDOSCOPIC PROCEDURES IN CANCER PATIENTS WITH NEUTROPENIA: FIVE YEARS CANCER CENTER EXPERIENCE. Gastrointestinal Endoscopy, 2018, 87, AB128.	0.5	0
68	Tu1724 - Outcomes of Immunotherapy-Induced Diarrhea and Colitis: A Cancer Center Experience. Gastroenterology, 2018, 154, S-1001.	0.6	0
69	Reply to J. Delyon et al. Journal of Clinical Oncology, 2019, 37, 3564-3565.	0.8	0
70	Su1163 ENDOSCOPIC ULTRASOUND GUIDED TISSUE ACQUISITION FOR GASTRIC CANCER DIAGNOSTIC PROFILING AS AN ADJUNCT TO ENDOSCOPIC MUCOSAL BIOPSIES. Gastrointestinal Endoscopy, 2019, 89, AB295.	0.5	0
71	Patients with non-colorectal cancers may be at elevated risk of colorectal neoplasia. Journal of Cancer, 2020, 11, 3192-3198.	1.2	0
72	Taming the Beast: The Safety and Efficacy of Fecal Microbiota Transplantation in Severe and Complicated Clostridium difficile Infection. American Journal of Gastroenterology, 2018, 113, S113-S115.	0.2	0

#	ARTICLE	IF	CITATIONS
73	Fecal Microbiota Transplantation for Clostridium difficile Infection in Immunocompromised Patients - Safe or Risky?. American Journal of Gastroenterology, 2018, 113, S115-S117.	0.2	0
74	Fearing the Unknown - The Fate of Inflammatory Bowel Disease After Fecal Microbiota Transplantation for Clostridium difficile Infection. American Journal of Gastroenterology, 2018, 113, S409-S411.	0.2	0
75	The Constellation of Upper Gastrointestinal Symptoms and Associated Endoscopic and Histologic Features in Patients Receiving Immune Checkpoint Inhibitors. American Journal of Gastroenterology, 2018, 113, S705.	0.2	0
76	Immune-Related Gastrointestinal Toxicities. , 2019, , .		0
77	Risk of colon adenoma in patients with breast cancer.. Journal of Clinical Oncology, 2019, 37, 1541-1541.	0.8	0
78	Risk of colonic adenoma in patients with nonâ€colorectal cancers.. Journal of Clinical Oncology, 2019, 37, e13070-e13070.	0.8	0